Please login to the form below

Not currently logged in
Email:
Password:

Dr Thomas Werner joins RIEMSER Pharma advisory board

Former GSK Germany head will support its international expansion
Dr Thomas Werner

German specialty pharmaceuticals company RIEMSER Pharma has appointed Dr Thomas Werner to its advisory board.

The former head of GlaxoSmithKline and Bristol-Myers Squibb Germany will primarily support the company's international expansion strategy.

Dr Kai Deusch, CEO of RIEMSER Pharma, said: "We are very proud to have Dr Thomas Werner on board. His vision and expertise in the pharmaceutical industry will help us to identify new products for our portfolio as part of our growth strategy and open new key markets. The appointment of Thomas Werner represents another step towards establishing RIEMSER Pharma as a leading specialty pharmaceutical company in Europe.”

Dr Werner worked at Bristol-Myers Squibb from 1983 to 1997, ending his time there as managing director for Germany, and then from 1997 to 2009 he served as CEO of GlaxoSmithKline Germany and Central Europe.

Since 2009 he has worked as an independent consultant and a member of the supervisory and advisory boards for a number of pharma companies.

Dr Werner said: "RIEMSER Pharma is an exceptionally promising company, which has already done an excellent job of positioning itself in the dynamic market of specialty pharmaceutical companies. I am looking forward to promoting RIEMSER Pharma's continued growth together with the management team by providing new impetus for strategic product and company acquisitions.”

16th December 2014

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

Pandemic preparedness
The pandemic preparedness paradox
Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...

Infographics